Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aligos Therapeutics, Inc. (ALGS)

0.747   0.017 (2.33%) 09-29 16:00
Open: 0.725 Pre. Close: 0.73
High: 0.7471 Low: 0.7201
Volume: 25,382 Market Cap: 32(M)

Technical analysis

as of: 2023-09-29 4:25:46 PM
Short-term rate:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Mid-term rate:       
Target: Six months: 0.98     One year: 1.07
Support: Support1: 0.71    Support2: 0.59
Resistance: Resistance1: 0.83    Resistance2: 0.91
Pivot: 0.77
Moving Average: MA(5): 0.72     MA(20): 0.79
MA(100): 0.96     MA(250): 1.12
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 12.5     %D(3): 5.7
RSI: RSI(14): 34.5
52-week: High: 2.41  Low: 0.71
Average Vol(K): 3-Month: 69 (K)  10-Days: 46 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ALGS ] has closed above bottom band by 30.5%. Bollinger Bands are 29.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.75 - 0.75 0.75 - 0.75
Low: 0.71 - 0.72 0.72 - 0.72
Close: 0.74 - 0.75 0.75 - 0.75

Company Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Headline News

Fri, 22 Sep 2023
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG ... - BioSpace

Thu, 21 Sep 2023
LES ACTIONS AMÉRICAINES EN MOUVEMENT-Fox Corp, Cisco Systems, Darden Restaurants - Boursorama

Thu, 21 Sep 2023
Aligos progresse alors que la FDA autorise le lancement d'essais cliniques pour un médicament contre la NASH - Boursorama

Thu, 03 Aug 2023
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results - Yahoo Finance

Mon, 31 Jul 2023
Checkpoint to sell 3.2M shares at $3.09 in registered direct offering - Seeking Alpha

Wed, 21 Jun 2023
Aligos Therapeutics Presents Data from its Liver Disease Programs ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 40 (M)
Shares Float 18 (M)
% Held by Insiders 16.2 (%)
% Held by Institutions 67.7 (%)
Shares Short 761 (K)
Shares Short P.Month 777 (K)

Stock Financials

EPS -1.93
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.6
Profit Margin (%) 0
Operating Margin (%) -490.9
Return on Assets (ttm) -36.7
Return on Equity (ttm) -79.7
Qtrly Rev. Growth 86.5
Gross Profit (p.s.) -1.77
Sales Per Share 0.42
EBITDA (p.s.) -2.05
Qtrly Earnings Growth 0
Operating Cash Flow -70 (M)
Levered Free Cash Flow -36 (M)

Stock Valuations

PE Ratio -0.39
PEG Ratio 0
Price to Book value 0.46
Price to Sales 1.74
Price to Cash Flow -0.44

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.